Clinical trial
Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee…
NCT04864392 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT04864392 |
|---|---|
| Title | Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis |
| Official title | A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis |
| Acronym | ONWARDS |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteoarthritis |
| Intervention type | Drug |
| Interventions | LNA043 Dosing Regimen A, LNA043 Dosing Regimen B, LNA043 Dosing Regimen C, LNA043 Dosing Regimen D, Placebo |
| Enrollment | 582 |
| Start date | May 31, 2021 |
| Primary completion | Sep 29, 2024 |
| Completion | May 29, 2025 |
| First posted | Apr 28, 2021 |
| Last update posted | Jul 24, 2025 |
| Countries | Argentina, Australia, Canada, China, Czechia, Denmark, Estonia, India, Japan, Mexico, Poland, Spain and 3 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: